company background image
AVRO

AVROBIONasdaqGS:AVRO Stock Report

Market Cap

US$260.9m

7D

-3.2%

1Y

-56.0%

Updated

25 Sep, 2021

Data

Company Financials +
AVRO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AVRO Overview

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide.

Price History & Performance

Summary of all time highs, changes and price drops for AVROBIO
Historical stock prices
Current Share PriceUS$5.98
52 Week HighUS$5.44
52 Week LowUS$20.07
Beta1.33
1 Month Change0%
3 Month Change-39.54%
1 Year Change-56.00%
3 Year Change-88.47%
5 Year Changen/a
Change since IPO-80.83%

Recent News & Updates

Aug 10
We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

May 05

AVROBIO: Fabrazyme's Full Approval Changes Things

Photo by designer491/iStock via Getty Images AVROBIO (AVRO) has been having a bad spate lately due to no fault of its own. I covered it in December, and by January, the stock was up 30%; but then, in February, bluebird bio's (BLUE) trial was halted, and AVRO went down 30%

Shareholder Returns

AVROUS BiotechsUS Market
7D-3.2%-2.3%0.1%
1Y-56.0%26.1%35.3%

Return vs Industry: AVRO underperformed the US Biotechs industry which returned 26.1% over the past year.

Return vs Market: AVRO underperformed the US Market which returned 35.3% over the past year.

Price Volatility

Is AVRO's price volatile compared to industry and market?
AVRO volatility
AVRO Beta1.33
Industry Beta1.03
Market Beta1

Stable Share Price: AVRO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: AVRO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015121Geoff MacKayhttps://www.avrobio.com

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company’s lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease.

AVROBIO Fundamentals Summary

How do AVROBIO's earnings and revenue compare to its market cap?
AVRO fundamental statistics
Market CapUS$260.87m
Earnings (TTM)-US$123.20m
Revenue (TTM)n/a

0x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVRO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$123.20m
Earnings-US$123.20m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.82
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did AVRO perform over the long term?

See historical performance and comparison

Valuation

Is AVROBIO undervalued compared to its fair value and its price relative to the market?

1.18x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AVRO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AVRO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AVRO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AVRO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVRO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AVRO is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is AVROBIO forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-4.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AVRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AVRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AVRO is forecast to have no revenue next year.

High Growth Revenue: AVRO is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AVRO is forecast to be unprofitable in 3 years.


Past Performance

How has AVROBIO performed over the past 5 years?

-43.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVRO is currently unprofitable.

Growing Profit Margin: AVRO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVRO is unprofitable, and losses have increased over the past 5 years at a rate of 43.6% per year.

Accelerating Growth: Unable to compare AVRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: AVRO has a negative Return on Equity (-55.75%), as it is currently unprofitable.


Financial Health

How is AVROBIO's financial position?


Financial Position Analysis

Short Term Liabilities: AVRO's short term assets ($233.5M) exceed its short term liabilities ($17.0M).

Long Term Liabilities: AVRO's short term assets ($233.5M) exceed its long term liabilities ($150.0K).


Debt to Equity History and Analysis

Debt Level: AVRO is debt free.

Reducing Debt: AVRO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVRO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AVRO has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 42.8% each year.


Dividend

What is AVROBIO current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVRO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVRO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Geoff MacKay (55 yo)

5.83yrs

Tenure

US$4,904,395

Compensation

Mr. Geoff MacKay, BSc, serves as Chief Executive Officer and President of AVROBIO Inc. He served as Director at RepliCel Life Sciences Inc. since December 2020 until 2021. Mr. MacKay serves as Chairman of...


CEO Compensation Analysis

Compensation vs Market: Geoff's total compensation ($USD4.90M) is above average for companies of similar size in the US market ($USD1.08M).

Compensation vs Earnings: Geoff's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AVRO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: AVRO's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AVRO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.7%.


Top Shareholders

Company Information

AVROBIO, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: AVROBIO, Inc.
  • Ticker: AVRO
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$260.866m
  • Shares outstanding: 43.62m
  • Website: https://www.avrobio.com

Number of Employees


Location

  • AVROBIO, Inc.
  • Building 300
  • Suite 201
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 22:03
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.